chevron_leftBack
As of 15 June 2026, Kura Oncology, Inc. has a market cap of $776.67M USD, ranking #12235 globally and #2341 in the United States.
It ranks #1118 in the Healthcare sector, and #207 in the Biotechnology industry.
Key Stats
Market Cap
$776.67MUSD
Enterprise Value
$132.55MUSD
Revenue (TTM)
$67.48MUSD
EBITDA (TTM)
-$302.6MUSD
Net Income (TTM)
-$278.67MUSD
PS Ratio
11.5
PB Ratio
4.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Troy Wilson
open_in_new
Employees
260
Founded
2014
Website
kuraoncology.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.9% | -8.2% | 13% | 8.8% | -17% | 34% |
News
Loading...
KURA Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
KURA
Kura Oncology Inc
ISIN: US50127T1097
Shares Out.:
Shares Outstanding:
88.774M1
Shares Float:
85.912M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
8.75 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
23K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
20K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
3K%
|
-
|
|
NYSE: IQV
|
$26.3B
3K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
3K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
2K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
6K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
6K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
5K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
5K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
4K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
3K%
|
-
|
chevron_leftBack